Skip to main navigation
Loading
  • News
  • Investors
  • Careers
  • Contact
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
    • What We Do
    • Partnering
  • Patients & Caregiver
    • Clinical Trials
    • Expanded Access Policy
    • Niemann-Pick Disease Type C
    • Urea Cycle Disorders
    • Vascular Ehlers-Danlos
  • Our Products
    • MIPLYFFA®
    • OLPRUVA ®
  • Our Pipeline
    • Pipeline
    • Clinical Trials
    • Publications & Presentations
    • Medical Literature
    • Medical Information
    • Investigator-Initiated Studies
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

Release Details

  • Overview
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Press Releases
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • IRS – Required Disclosures
  • State Compliance
  • SEC Filings
  • Contact
  • Email Alerts
  • FAQs

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

February 2, 2026 at 7:30 AM EST
PDF Version

CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been invited to ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's trading session.

The opening bell ceremony can be seen live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony and on the Nasdaq MarketSite Tower at 43rd and Broadway in New York, NY.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Investor Contact

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com  

Media Contact

Julie Downs
+1 (508) 246-3230
jdowns@zevra.com


  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
    • What We Do
    • Partnering
  • Patients & Caregiver
    • Clinical Trials
    • Expanded Access Policy
    • Niemann-Pick Disease Type C
    • Urea Cycle Disorders
    • Vascular Ehlers-Danlos
  • Our Products
    • MIPLYFFA®
    • OLPRUVA ®
  • Our Pipeline
    • Pipeline
    • Clinical Trials
    • Publications & Presentations
    • Medical Literature
    • Medical Information
    • Investigator-Initiated Studies
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2026 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use

Scroll to top